{"filings":[{"id":555237,"accession_number":"0001104659-26-064540","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2026-05-20T20:29:06+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Senseonics shareholders approve doubling authorized shares to 140M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increase authorized common stock from 70M to 140M shares, effective May 20, 2026.","Elected directors Timothy T. Goodnow, Francine R. Kaufman, and Sharon Larkin.","Advisory vote on executive compensation passed: 10.4M for, 2.4M against.","Ratified KPMG as independent auditor for FY 2026 with 21.1M votes for.","Approved 2026 Equity Incentive Plan with 10.5M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94111,"accession_number":"0001104659-26-057142","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senseonics Q1 revenue up 87% to $11.7M; raises FY2026 guidance to $60-64M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $11.7M (+87% YoY); US $9.3M, OUS $2.4M.","Gross margin 59% (+35pp YoY); gross profit $6.9M vs $1.5M.","Net loss $32.3M ($0.71/sh) vs $14.3M ($0.40/sh); SG&A surged $22.5M on commercial transition.","Raised $92M equity plus expanded Hercules debt facility; cash $64.6M, debt $35.2M.","FY2026 revenue guidance raised to $60-64M (prev. $58-62M); gross margins expected 55-58%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":11711000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94110,"accession_number":"0001104659-26-054861","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Senseonics amends loan agreement; up to $140M total, $20M expected to fund May 6","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended loan agreement with Hercules Capital expands total commitment to $140M, with $80M committed and $60M uncommitted.","$10M Tranche 2 and $10M Tranche 3A loans expected to fund at closing on May 6, 2026.","Loans bear interest at greater of prime+2.40% or 9.90%; mature September 3, 2029.","Interest-only payments through Oct 1, 2028; prepayment fee of 1-3% applies before Maturity.","Additional warrants issued with each tranche at 2% of funded loan amount / VWAP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94109,"accession_number":"0001104659-26-053515","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","2.02","7.01","8.01","9.01"],"status":"ready","headline":"Senseonics prices $80M public offering, reports preliminary Q1 revenue $11.7M and net loss $31-33M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Offering: 8M shares + 8M pre-funded warrants at $5.00; net proceeds ~$74.7M ($86M if overallotment exercised). Underwriters have 30-day option for 2.4M additional shares.","Preliminary Q1 2026 results: revenue $11.7M, gross margin 54%, net loss $31-33M; cash & equivalents $64.6M; equity $33.7-35.7M. Full results due May 7.","Non-binding term sheet to amend Hercules credit facility: capacity increases to $140M; $20M near-term commitments ($10M Tranche 2 at closing, $10M Tranche 3A). Definitive amendment expected early May.","Closing of offering expected May 4, 2026. Proceeds to fund Eversense 365 launch and pipeline development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":11711000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106241,"accession_number":"0001104659-26-027055","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Senseonics signs local asset purchase agreements for Eversense CGM business in Italy, Germany, Spain, and Sweden","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On March 12, 2026, Senseonics entered into Local Purchase Agreements to acquire Ascensia's Eversense CGM assets in four European countries.","Consideration is cash payment of Net Book Value; closing expected on or before June 30, 2026.","Transition Services Agreement signed to support logistics, IT, regulatory, and commercial continuity through June 30, 2026.","Transactions were contemplated by the Master Asset Purchase Agreement with Ascensia disclosed on January 2, 2026.","Company assumes commercial responsibility for Eversense in European Territories, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106240,"accession_number":"0001104659-26-022293","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senseonics Q4 revenue $14.3M (+72% YoY); guides FY26 revenue $58-62M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $14.3M (+72% YoY); US revenue $12.1M vs $6.2M in Q4 2024.","Full year 2025 revenue $35.3M (+57% YoY); net loss $69.1M ($1.66 loss per share).","Received CE Mark for Eversense 365 in EU; FDA IDE approved for Gemini sensor pivotal trial.","2026 revenue guidance $58-62M (65-76% growth); gross margin expected ~50%.","Transitioned Eversense commercialization in-house; launched twiist AID system integration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106239,"accession_number":"0001104659-26-002736","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Senseonics Q4 2025 preliminary revenue $14.2M (+71% YoY); FY2025 $35.2M; guides FY2026 $58-62M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 revenue $14.2M (+71% YoY); FY2025 revenue $35.2M (+57% YoY); cash $94.3M.","Patient base grew 103% in Q4 2025 vs Q4 2024; largest new patient addition in company history.","Received FDA IDE approval to begin pivotal trial for self-powered Gemini sensor; first patients enrolled.","2026 revenue guidance $58-62M (65-76% growth); gross margin ~50%; commercial transition from Ascensia effective Jan 1, 2026.","First commercial patients using pump partner Sequel's twiist insulin delivery system with Eversense 365 compatibility."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":35257000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106238,"accession_number":"0001104659-26-000056","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","5.02"],"status":"ready","headline":"Senseonics closes $1.1M acquisition of U.S. Eversense assets from Ascensia","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["U.S. asset purchase closed Jan 1, 2026; cash consideration ~$1.1M for inventory, licenses, and leases.","European asset purchases (Italy, Germany, Spain, Sweden) expected to close by June 30, 2026, subject to local agreements.","Amended collaboration agreement gives Senseonics 100% of European Eversense revenues from Jan 1; Ascensia's U.S. rights terminated.","Director Koichiro Sato (PHC Holdings) resigned from board effective Dec 31, 2025; PHC retains designation right but won't currently exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122539,"accession_number":"0001104659-25-107004","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senseonics Q3 revenue $8.1M (+90% YoY); guides FY25 rev ~$35M; planning commercial transition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $8.1M vs $4.3M YoY; U.S. revenue $6.4M (+167% YoY).","Net loss $19.5M ($0.43/share) improved from $24.0M ($0.77/share) in Q3 2024.","Full-year 2025 revenue guidance ~$35M; gross margins 35-40%; cash used in ops ~$60M.","Signed MOU with Ascensia to transition Eversense commercial responsibility back to Senseonics.","1-for-20 reverse split effective Oct 17; listing to transfer from NYSE American to Nasdaq on Nov 17."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":21001000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122538,"accession_number":"0001104659-25-100097","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Senseonics Holdings announces 1-for-20 reverse stock split effective October 17, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio is 1-for-20, combining every 20 shares into 1.","Authorized shares reduced from 1.4 billion to 70 million, effective at 4:05 p.m. ET on Oct 17, 2025.","No fractional shares will be issued; stockholders receive cash in lieu of fractional shares.","Common stock to trade on NYSE American under ticker SENS on a split-adjusted basis from Oct 20, 2025.","Proportionate adjustments made to outstanding stock options, RSUs, warrants, and equity plan reserves."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122537,"accession_number":"0001104659-25-097581","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":[],"status":"ready","headline":"Senseonics reports preliminary Q3 2025 revenue of ~$8.1M, up 91% YoY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited Q3 2025 revenue of approximately $8.1 million versus $4.2 million in Q3 2024.","Revenue growth of 91% YoY driven by approximately 160% new patient growth in the U.S.","Figures are preliminary, subject to completion of financial close and independent auditor review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122536,"accession_number":"0001104659-25-097124","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Senseonics Q3 preliminary revenue $8.1M (+91% YoY); 1:20 reverse stock split effective Oct 17","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited revenue $8.1M for Q3 2025, up 91% vs Q3 2024.","US new patient starts grew ~160% YoY; September set record monthly starts.","1:20 reverse stock split reduces shares from ~816M to ~41M; effective 5:00 pm ET Oct 17, trading post-split Oct 20.","Sales and marketing organization brought in-house; DTC marketing driving awareness and patient growth.","Reverse split approved by stockholders Sep 29; Board set final ratio Oct 3."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":21001000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139234,"accession_number":"0001104659-25-095010","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Senseonics shareholders approve reverse stock split of 1-for-10 to 1-for-20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved at special meeting on Sept 29, 2025; votes: 285.6M for, 178.2M against, 5.0M abstain.","Split range 1-for-10 to 1-for-20, with proportionate reduction in authorized shares.","Board may implement split at any time before Sept 29, 2026, at its sole discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139233,"accession_number":"0001104659-25-087170","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Senseonics to take Eversense commercialization in-house, expands debt to $100M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MOU with Ascensia to transfer global Eversense commercialization to Senseonics by Jan 1, 2026; assets bought at book value.","Brian Hansen, Ascensia's CGM President, named Senseonics CCO effective Jan 1, 2026.","Amended Hercules loan facility increased to $100M total; $35M funded immediately at WSJ prime + 2.40% (floor 9.90%).","FY 2025 revenue outlook reaffirmed at $34-38M; 2026 gross margin expected ~50%, scaling to >70%.","Existing warrants exercise price reduced to $0.4545; additional warrants issuable on future tranches."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139232,"accession_number":"0001558370-25-010508","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senseonics Q2 revenue $6.6M (+37% YoY); net loss narrows to $14.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.6M, up 37% YoY, driven by 79% U.S. new patient starts growth to $4.9M.","Net loss $14.5M ($0.02 loss per share) vs $20.3M loss in Q2 2024; gross profit $3.1M vs $0.3M.","FY2025 revenue guidance reaffirmed at $34-38M; gross margins expected 32.5%-37.5%.","Raised $77.8M gross proceeds ($57.5M public offering + $20.3M Abbott private placement).","Entered development agreement with Sequel Med Tech to integrate Eversense 365 with twiist AID system."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":12906000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156792,"accession_number":"0001104659-25-051602","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Senseonics shareholders elect directors, approve say-on-pay and KPMG ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four director nominees elected: DeFalco, Hansen, Prince, Roeder; broker non-votes ~177M each.","Advisory vote on executive compensation passed: 154.4M for, 18.9M against, 1.4M abstain.","Ratification of KPMG as auditor for FY2025 passed: 336.1M for, 11.5M against, 4.0M abstain.","Turnout: 351.7M shares (53.75%) of 654.2M outstanding present or represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156788,"accession_number":"0001104659-25-050221","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K/A","filed_at":"2025-05-19T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Senseonics files technical amendment to prior 8-K; no new material information","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Amendment to Form 8-K filed May 16, 2025, dated May 15, 2025.","Only replaces Exhibit 5.1 (legal opinion of Cooley LLP) and Exhibit 23.1 (consent).","No changes to any other information in the original report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156791,"accession_number":"0001104659-25-050090","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Senseonics prices $50M public offering of 100M shares at $0.50; Abbott to purchase $25M in concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 100M shares priced at $0.50/share, with 15M-share overallotment option to underwriters.","Net proceeds expected ~$45.4M ($52.45M if overallotment exercised); closing May 19, 2025.","Abbott Laboratories will purchase $25M of common stock at $0.50/share in a separate private placement closing May 21, 2025.","Proceeds to fund Eversense 365 launch, pipeline development, and working capital.","TD Cowen and Barclays lead as joint book-running managers; RBC Capital Markets and Lake Street as bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156790,"accession_number":"0001104659-25-049437","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Senseonics enters $25M private placement with Abbott; terminates ATM program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $25M of common stock sold to Abbott at public offering price, closing within 2 days after public offering.","Abbott receives info rights on Gemini/Freedom products and exclusive negotiation period for strategic transactions until 2032 or FDA clearance of Freedom.","Company terminates Goldman Sachs ATM equity distribution agreement in connection with proposed public offering.","Private placement price equals per-share price of concurrent public offering, capped at 4.99% beneficial ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156789,"accession_number":"0001558370-25-006972","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senseonics Q1 revenue $6.3M, up 24% YoY; net loss narrows to $14.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.3M vs $5.0M YoY (+24%); U.S. $4.5M, OUS $1.8M.","Net loss $14.3M ($0.02/sh) compared to $18.9M ($0.03/sh) in Q1 2024.","Gross profit improved to $1.5M from $0.3M driven by Eversense 365 margins.","CMS updated physician fee schedule retroactive to Jan 1 for Eversense 365; CE Mark submitted for EU launch H2 2025.","Full year 2025 revenue guidance $34-38M; gross margins 25-30%; cash used in ops $50-60M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":6257000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175194,"accession_number":"0001558370-25-002038","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senseonics Q4 revenue $8.3M, net loss $15.5M; guides FY25 revenue $34-38M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $8.3M (up from $8.0M YoY); net loss $15.5M ($0.02 loss per share).","Full-year 2024 revenue $22.5M (flat YoY); net loss $78.6M ($0.12 loss per share).","Patient base grew 56% in 2024 to ~6,000 global patients; Eversense 365 FDA approved and launched.","FY2025 guidance: revenue $34-38M, gross margins 25-30%, cash usage $50-60M.","Post-quarter: raised ~$27M via ATM, repaid $20.4M convertible notes; debt reduced to $35M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175193,"accession_number":"0001104659-25-004468","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Anthony Raab resigns from Senseonics board effective Jan. 17, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Raab notified the Board of his resignation on January 17, 2025.","Resignation is to focus on professional investment career, other board roles, and family.","No disagreement with Company, management, or Board regarding operations or policies.","No replacement for the vacant board seat has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175192,"accession_number":"0001104659-25-002855","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Senseonics reports preliminary 2024 revenue of $22.5M, patient base up 56%, cancels reverse stock split meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 revenue ~$8.3M; full year 2024 revenue ~$22.5M.","Patient base grew 56% to ~6,000 global patients; over 1,000 US prescribers in 2024.","December new patient shipments ~600, highest monthly total; DTC leads doubled in Q4.","Cash, equivalents, restricted cash ~$74.9M at Dec 31, 2024; operating expenses guided.","Cancelled special meeting for reverse stock split after share price appreciation; proxies favored split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192133,"accession_number":"0001104659-24-120650","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Senseonics updates corporate presentation at Stifel Healthcare Conference","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Presentation highlights Eversense 365 CGM system FDA clearance and commercial launch.","Collaboration with Mercy Health targeting up to 30,000 patients initiated Q3 2024, expansion expected 2025.","Gemini (self-powered) and Freedom (no transmitter) development programs progressing with IDE filing planned 2025.","CGM market opportunity described as $20B+ US TAM with ~21% CAGR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192132,"accession_number":"0001104659-24-115315","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senseonics Q3 revenue $4.3M, gross loss $4.1M; Eversense 365 launch underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $4.3M, down ~30% YoY from $6.1M; U.S. revenue $2.4M vs $3.9M.","Gross loss $4.1M vs gross profit $1.2M, driven by $4.8M one-time charges for Eversense 365 transition.","Net loss $24.0M ($0.04/share), essentially flat vs $24.1M in Q3 2023.","Cash $74.8M, debt $55.9M; raised $16M post-quarter; FY2024 revenue guidance ~$22M.","FDA approved Eversense 365 (365-day CGM); first commercial insertion at Mercy; restructuring targets $10M cash OPEX cut in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":14175000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192131,"accession_number":"0001104659-24-111627","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Senseonics prices $16M registered direct offering at $0.35/share with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["45,714,286 shares and matching warrants sold at combined $0.35 per unit.","Gross proceeds $16M upfront; warrants could yield additional $16M if exercised for cash.","Warrants exercisable after 6 months at $0.35, expire 5 years from initial exercise.","Proceeds for working capital, general corporate, and possible repayment of 5.25% Convertible Notes due 2025.","ATM equity distribution agreement amended to allow up to $55M in common stock sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208624,"accession_number":"0001104659-24-087268","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q2 revenue $4.9M (+18% YoY), net loss $20.3M; 365-day Eversense Q4 launch on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $4.9M, up 18% vs $4.1M in Q2 2023; U.S. revenue $3.0M (+67%), OUS $1.9M.","Net loss $20.3M ($0.03/sh) vs $20.4M ($0.04/sh); gross profit slipped to $0.3M from $0.4M.","FY 2024 revenue guidance unchanged at $22M-$24M; cash burn expected ~$70M, in line with 2023.","FDA 510(k) review ongoing for 365-day Eversense; planned Q4 launch; Gemini System first-in-human testing began.","Eon Care Services subsidiary formed; Mercy collaboration RPM service initial insertions expected Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":9912000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226337,"accession_number":"0001104659-24-074005","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Senseonics sees H1 2024 net rev $10M, +21% YoY; FY 2024 guidance $22-24M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirmed H1 2024 global net revenue $10M, 21% growth over H1 2023.","US new patient starts H1 2024 >200% higher than H1 2023.","FDA 510(k) for 365-day Eversense on track for Q4 2024 launch.","Mercy Health collaboration initiated; first insertions targeted Q3 2024.","FY 2024 revenue guidance $22-24M; cash utilization ~$70M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226336,"accession_number":"0001104659-24-064335","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Senseonics stockholders approve increase in authorized common shares from 900M to 1.4B","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to certificate of incorporation increases authorized common stock from 900M to 1.4B shares.","Approved with 155,991,595 votes for, 119,606,483 against, 4,814,664 abstain; filed with Delaware on May 22, 2024.","Three director nominees elected: Edelman, Fiorentino, Raab; advisory say-on-pay and KPMG ratification also passed.","Shareholder turnout of 52.83% (280,412,742 shares present)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226335,"accession_number":"0001104659-24-060535","cik":1616543,"company_name":"Senseonics Holdings, Inc.","ticker":"SENS","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Senseonics Q1 revenue up 22% to $5.1M; net loss $18.9M vs income $1.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.1M (+22% YoY); U.S. $3.7M (+76%), OUS $1.4M (-30%).","Net loss $18.9M ($0.03 diluted loss) vs net income $1.3M in Q1 2023, driven by non-cash derivative accounting.","First half 2024 revenue outlook unchanged at $10M (~16% growth YoY).","Received iCGM designation for Eversense; FDA 510(k) filed for 365-day system.","Collaboration with Mercy health system to manage 30,000 potential CGM users."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":5047000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":332532894.3069621,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}